| Literature DB >> 30425058 |
Ruth C Travis1, Aurora Perez-Cornago2, Paul N Appleby1, Demetrius Albanes3, Corinne E Joshu4, Pamela L Lutsey5, Alison M Mondul6, Elizabeth A Platz4, Stephanie J Weinstein3, Tracy M Layne3, Kathy J Helzlsouer4, Kala Visvanathan4, Domenico Palli7, Petra H Peeters8, Bas Bueno-de-Mesquita9,10,11,12, Antonia Trichopoulou13, Marc J Gunter14, Konstantinos K Tsilidis11,15, Maria-Jose Sánchez16,17, Anja Olsen18, Hermann Brenner19,20,21, Ben Schöttker19,22, Laura Perna19, Bernd Holleczek23, Paul Knekt24, Harri Rissanen24, Bu B Yeap25,26, Leon Flicker25,27,28, Osvaldo P Almeida25,27,29, Yuen Yee Elizabeth Wong25,30, June M Chan31, Edward L Giovannucci32, Meir J Stampfer32, Giske Ursin33, Randi E Gislefoss33, Tone Bjørge33,34, Haakon E Meyer35,36, Rune Blomhoff37,38, Shoichiro Tsugane39, Norie Sawada39, Dallas R English40,41, Darryl W Eyles42, Alicia K Heath11, Elizabeth J Williamson43, Jonas Manjer44, Johan Malm44, Martin Almquist45, Loic Le Marchand46, Christopher A Haiman47, Lynne R Wilkens46, Jeannette M Schenk48, Cathy M Tangen49,50, Amanda Black3, Michael B Cook3, Wen-Yi Huang3, Regina G Ziegler3, Richard M Martin51,52,53, Freddie C Hamdy54, Jenny L Donovan51, David E Neal54, Mathilde Touvier55, Serge Hercberg55, Pilar Galan55, Mélanie Deschasaux55, Timothy J Key1, Naomi E Allen56.
Abstract
Previous prospective studies assessing the relationship between circulating concentrations of vitamin D and prostate cancer risk have shown inconclusive results, particularly for risk of aggressive disease. In this study, we examine the association between prediagnostic concentrations of 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH)2D] and the risk of prostate cancer overall and by tumor characteristics. Principal investigators of 19 prospective studies provided individual participant data on circulating 25(OH)D and 1,25(OH)2D for up to 13,462 men with incident prostate cancer and 20,261 control participants. ORs for prostate cancer by study-specific fifths of season-standardized vitamin D concentration were estimated using multivariable-adjusted conditional logistic regression. 25(OH)D concentration was positively associated with risk for total prostate cancer (multivariable-adjusted OR comparing highest vs. lowest study-specific fifth was 1.22; 95% confidence interval, 1.13-1.31; P trend < 0.001). However, this association varied by disease aggressiveness (P heterogeneity = 0.014); higher circulating 25(OH)D was associated with a higher risk of nonaggressive disease (OR per 80 percentile increase = 1.24, 1.13-1.36) but not with aggressive disease (defined as stage 4, metastases, or prostate cancer death, 0.95, 0.78-1.15). 1,25(OH)2D concentration was not associated with risk for prostate cancer overall or by tumor characteristics. The absence of an association of vitamin D with aggressive disease does not support the hypothesis that vitamin D deficiency increases prostate cancer risk. Rather, the association of high circulating 25(OH)D concentration with a higher risk of nonaggressive prostate cancer may be influenced by detection bias. SIGNIFICANCE: This international collaboration comprises the largest prospective study on blood vitamin D and prostate cancer risk and shows no association with aggressive disease but some evidence of a higher risk of nonaggressive disease. ©2018 American Association for Cancer Research.Entities:
Mesh：
Substances：
Year: 2018 PMID： 30425058 PMCID： PMC6330070 DOI： 10.1158/0008-5472.CAN-18-2318
Source DB: PubMed Journal: Cancer Res ISSN： 0008-5472 Impact factor: 12.701